
Insmed (INSM) Stock Forecast & Price Target
Insmed (INSM) Analyst Ratings
Bulls say
Insmed Inc is positioned for substantial growth, with an estimated 500,000 to 1 million diagnosed patients for Mycobacterium Avium Complex lung disease, paired with high misdiagnosis rates that could lead to increased market potential. The company has reiterated its global revenue guidance for ARIKAYCE at $405 million to $425 million for 2025, complemented by the anticipated strong launch of brensocatib, expected to target an $8.2 billion peak sales opportunity in bronchiectasis. Additionally, Insmed's expanded commercial infrastructure, including the addition of 120 sales representatives and further plans for market access enhancement, underlines the company's proactive approach to capitalize on its growing pipeline and potential label expansions.
Bears say
Insmed Inc. faces considerable risks that contribute to a negative outlook on its stock, including potential setbacks in clinical trials and regulatory approvals for its pipeline drugs, which could impede revenue generation. The company reported significant net losses of $235.5 million for the fourth quarter of fiscal 2024 and $913.8 million for the entire fiscal year, raising concerns about its financial sustainability given the substantial investment required for ongoing research and development. Additionally, uncertainties surrounding payer dynamics, the emergence of unforeseen safety signals, and the competitive landscape could further hinder Insmed's ability to successfully commercialize its products and meet its financial obligations.
This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.
Insmed (INSM) Analyst Forecast & Price Prediction
Start investing in Insmed (INSM)
Order type
Buy in
Order amount
Est. shares
0 shares